Xiha Biotechnology, the trailblazer in universal cell therapy for Parkinson's disease, has successfully concluded a C/C+ round of financing, amassing a substantial 500 million yuan. This achievement underscores the company's sixth consecutive year of triumphant market-oriented funding endeavors. The infusion of capital from this financing round will empower Xiha Biotechnology to propel several of its groundbreaking allogeneic universal iPSC-derived cell-based new drugs, which are either the first of their kind in China or globally, into the pivotal confirmatory clinical stage. Simultaneously, it will bolster the production and quality control capabilities for its "off-the-shelf" neural cell-based new drugs, paving the way for the broad commercial utilization of universal cell-based new drugs. Founded by the visionary Dr. Li Xiang, Xiha Biotechnology prides itself on its professional team, which has pioneered new technologies and platforms. The company has also applied for over 40 invention patents, establishing a robust global intellectual property system. With a laser focus on developing clinical-grade iPSC-derived neural cell-based new drugs for the treatment of major or critical nervous system diseases, Xiha Biotechnology has already initiated registered clinical trials in both China and the United States, marking its global footprint in the biopharmaceutical landscape.